{"filing":{"accession_number":"0001193125-26-279483","cik":"0001750284","ticker":"OLMA","company_name":"Olema Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"olma-20260617.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526279483/olma-20260617.htm"},"events":[{"id":13190,"run_id":11706,"accession_number":"0001193125-26-279483","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the results of Olema's June 17, 2026 annual meeting of stockholders. The filing presents final voting tallies for three proposals: election of four Class III directors (all elected), advisory approval of executive compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. The disclosure directly matches the shareholder_vote_results event type and is material to investors assessing governance and board composition.","company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10268,"accession_number":"0001193125-26-279483","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Olema's June 17, 2026 annual meeting of stockholders. The filing presents final voting tallies for three proposals: election of four Class III directors (all elected), advisory approval of executive compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. The disclosure directly matches the shareholder_vote_results event type and is material to investors assessing governance and board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:21:36.923843+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10268,"accession_number":"0001193125-26-279483","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Olema's June 17, 2026 annual meeting of stockholders. The filing presents final voting tallies for three proposals: election of four Class III directors (all elected), advisory approval of executive compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. The disclosure directly matches the shareholder_vote_results event type and is material to investors assessing governance and board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:21:36.923843+00:00","company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","filing_date":"2026-06-23"}]}